Abstract | PURPOSE: METHODS: We retrospectively reviewed consecutive patients with GEM-refractory PC who received FGS at our institution from March 2009 to December 2013. GEM was administered by fixed dose rate intravenous infusion of 1,200 mg/m(2) as a 120-min infusion on day 1, and S-1 was administered orally twice a day at a dose of 40 mg/m(2) on days 1-7. Cycles were repeated every 14 days. RESULTS: Sixty-one patients with GEM-refractory PC received FGS. Sixteen patients received FGS as third-line treatment. Twenty-nine patients (48 %) had a history of S-1 administration. The objective response rate was 13 %, and the disease control rate was 49 %. The median progression-free survival time was 2.7 months, and the median overall survival time was 6.0 months. Major Grade 3 or 4 adverse events included neutropenia (15 %), diarrhea (3 %), anorexia (2 %), and fatigue (2 %). A high inflammation-based prognostic score (modified Glasgow prognostic score (mGPS), which incorporates C-reactive protein and albumin), a performance status >0, and serum carbohydrate antigen 19-9 level >2,000 IU/ml were independently associated with a poor outcome. CONCLUSIONS:
|
Authors | Akiyoshi Kasuga, Naohiro Okano, Daisuke Naruge, Hiroshi Kitamura, Atsuko Takasu, Fumio Nagashima, Junji Furuse |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 75
Issue 3
Pg. 457-64
(Mar 2015)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 25547407
(Publication Type: Journal Article)
|
Chemical References |
- Drug Combinations
- Deoxycytidine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- Drug Combinations
- Female
- Humans
- Inflammation
(drug therapy, pathology)
- Infusions, Intravenous
- Male
- Middle Aged
- Oxonic Acid
(administration & dosage)
- Pancreatic Neoplasms
(drug therapy, pathology)
- Prognosis
- Retrospective Studies
- Salvage Therapy
- Survival Rate
- Tegafur
(administration & dosage)
- Treatment Outcome
- Gemcitabine
|